GAM
RGNX icon

Gemmer Asset Management’s Regenxbio RGNX Stock Holding History

Gemmer Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$4K – 1388
2020
Q2 		$4K Buy
+100
New +$3.73K ﹤0.01% 966
2020
Q1 		– Sell
-63
Closed -$3K – 1404
2019
Q4 		$3K Buy
+63
New +$2.49K ﹤0.01% 1161

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Gemmer Asset Management's RGNX Position: Q3 2020 in Review

Gemmer Asset Management sold out of Regenxbio (RGNX) in Q3 2020, closing a stake of 100 shares — an estimated $4K sold.

Gemmer Asset Management first reported a position in RGNX in Q4 2019 and held it in 2 quarters. The position peaked at $4K in Q2 2020. 166 funds tracked by Wall St. Rank hold RGNX as of Q3 2020.

  • Gemmer Asset Management reported no remaining Regenxbio position as of Q3 2020 after selling out during the quarter.
  • Gemmer Asset Management sold 100 Regenxbio shares in Q3 2020, an estimated $4K.
  • Gemmer Asset Management first reported a position in Regenxbio in Q4 2019 and held it in 2 quarters.
  • Gemmer Asset Management's Regenxbio position peaked at $4K in Q2 2020.
  • 166 funds tracked by Wall St. Rank held Regenxbio as of Q3 2020.

Based on Gemmer Asset Management's 13F filing for Q3 2020, filed 21 Oct 2020.